Musculoskeletal News and Research RSS Feed - Musculoskeletal News and Research

Study finds early symptoms of knee osteoarthritis in people who use stairs

Study finds early symptoms of knee osteoarthritis in people who use stairs

People who suffer from knee pain when using the stairs may be experiencing the early symptoms of osteoarthritis, according to a new study by University of Leeds experts. [More]
Asian and Hispanic patients with lupus have lower mortality rates

Asian and Hispanic patients with lupus have lower mortality rates

A new study by researchers from Brigham and Women's Hospital in Boston, Massachusetts reveals that Asian and Hispanic patients with systemic lupus erythematosus (SLE) have lower mortality rates compared to Black, White, or Native Americans with the disease. [More]
Medical co-morbidities associated with direct maternal deaths in the UK

Medical co-morbidities associated with direct maternal deaths in the UK

Medical co-morbidities, when women have one or more medical conditions, are found to be an important factor associated with direct maternal deaths, suggests a new study published today (9 January) in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG). [More]
Duke researchers grow contracting human skeletal muscle in lab

Duke researchers grow contracting human skeletal muscle in lab

In a laboratory first, Duke researchers have grown human skeletal muscle that contracts and responds just like native tissue to external stimuli such as electrical pulses, biochemical signals and pharmaceuticals. [More]
MTF Wound Care division inks group purchasing deal with Premier

MTF Wound Care division inks group purchasing deal with Premier

The Musculoskeletal Transplant Foundation Wound Care division announced today that it has signed a group purchasing agreement with Premier, Inc., a leading healthcare improvement company. The agreement offers Premier alliance members access to MTF Wound Care's innovative line of biologic tissue forms. [More]
InformedDNA and NIA Magellan to jointly offer evidence-based genetic benefits optimization program

InformedDNA and NIA Magellan to jointly offer evidence-based genetic benefits optimization program

InformedDNA announced today that it will collaborate with NIA Magellan, a division of Magellan Health, Inc., to offer an evidence-based genetic benefits optimization program. InformedDNA's national network of independent board-certified genetics specialists provides expert clinical review services to ensure appropriate use of genetic testing and improve patient care, while at the same time delivering significant cost savings. [More]
Whole-genome sequencing can identify patients' risk for hereditary cancer

Whole-genome sequencing can identify patients' risk for hereditary cancer

UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients' risk for hereditary cancer, which can potentially lead to improvements in cancer prevention, diagnosis, and care. [More]
Bio2 Technologies' CLM Bioactive Scaffold receives FDA clearance

Bio2 Technologies' CLM Bioactive Scaffold receives FDA clearance

Bio2 Technologies, Inc. (a privately held development stage company) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its CLM Bioactive Scaffold. [More]
Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Newly published research provides the first demonstration of how a genetic mutation associated with a common form of albinism leads to the lack of melanin pigments that characterizes the condition. [More]
Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

It may seem counterintuitive, but exercise can be beneficial for people suffering from arthritis and other muscle and joint conditions. A new study at Hospital for Special Surgery finds that older adults experienced less pain, reduced stiffness and less fatigue after participating in a hospital-based exercise program. [More]

Intronix Technologies, Western University collaborate to develop rehabilitation devices

Intronix Technologies will be collaborating with Western University's Department of Electrical and Computer Engineering to develop technology to be incorporated into rehabilitation devices. [More]
Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco. [More]
Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. [More]
IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL). [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program. [More]
IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM). [More]
Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT). [More]
CareCore, MedSolutions complete merger agreement

CareCore, MedSolutions complete merger agreement

CareCore National, LLC and MedSolutions, Inc., two leading providers of Specialty Benefits Management (SBM) services to managed care organizations and risk-bearing provider organizations, today announced the completion of a merger that will help advance the companies' collective commitment to containing healthcare costs and achieving quality medical outcomes. [More]
Disease-associated malnutrition imposes economic burden on society

Disease-associated malnutrition imposes economic burden on society

Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition. Because of the impact on patient health, disease-associated malnutrition imposes a significant economic burden on society of $157 billion per year, according to new research published in a supplemental issue of the Journal of Parenteral and Enteral Nutrition and supported by Abbott. [More]